Tag: Antibody-drug Conjugates

Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...

Antibody-drug conjugates (ADCs) have a well-known failure mode that has nothing to do with target selection. A company can identify an antibody with excellent affinity for a validated tumor antigen, attach a potent cytotoxic payload to it, and still watch the resulting conjugate underperform in the clinic, not because the biology was wrong, but because the molecule never distributed through the tumor the way the binding assay predicted it would. A new agreement between two Swiss life-sciences companies, Debiopharm and FluoSphera, is aimed squarely at that gap, the space between knowing an antibody binds its target and knowing what it does once it is actually inside a tumor.

Lonza Expands ADC Capabilities with Strategic Investments and Integrated Technologies

Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads

Wuxi and the Development of Antibody-Drug Conjugates: A Balanced Perspective

Antibody–drug conjugates (ADCs) are a rapidly evolving class of targeted chemotherapeutics that combine the tumor selectivity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule payloads. Through rational linker design and optimized bioconjugation, ADCs have steadily advanced toward the goal of precision cancer therapy, achieving enhanced efficacy and reduced off-target toxicity. As of 2026, more than 15 ADCs have been approved globally for hematologic and solid tumors, with over 2,000 candidates in development and worldwide sales projected to exceed $16 billion

Gilead Accelerate Its Oncology ADC Pipeline by Acquiring Tubulis for $5B

Antibody-Drug Conjugates in Oncology: Why Potency Is No Longer the Limiting Factor

The Most Interesting Activity in ADC Development is no Longer Happening in Traditional Formats

By combining antibody specificity with cytotoxic drug potency, antibody-drug conjugates (ADCs) continue to be a promising class of targeted therapies. However, despite significant advancements in the development of ADC, challenges such as limited efficacy, often attributed to tumor heterogeneity and resistance development, remain present. To overcome some of the complexities and challenges in the development of ADCs, Swiss-based Debiopharm and NetTargets, a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, have agreed to collaborate in developing the next-generation, dual-payload ADCs designed to overcome acquired resistance mechanisms in difficult-to-treat cancers.